US Patent

US9149532 — Pharmaceutical composition

Formulation · Assigned to Daiichi Sankyo Co Ltd · Expires 2028-03-28 · 2y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a pharmaceutical composition containing edoxaban tosylate or a pharmacologically acceptable salt or hydrate thereof, with a sugar alcohol or water-swelling additive.

USPTO Abstract

To provide pharmaceutical preparation exhibiting satisfactory dissolution property in a wide pH range. The pharmaceutical composition is characterized by containing (A) N 1 -(5-chloropyridin-2-yl)-N 2 -((1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-{[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]amino}cyclohexyl)ethanediamide, represented by the following formula (1), a pharmacologically acceptable salt thereof, or a hydrate of any of these, and (B) one or more species selected from the group consisting of a sugar alcohol and a water-swelling additive.

Drugs covered by this patent

Patent Metadata

Patent number
US9149532
Jurisdiction
US
Classification
Formulation
Expires
2028-03-28
Drug substance claim
No
Drug product claim
Yes
Assignee
Daiichi Sankyo Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.